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ABSTRACT: 4-Phenylbutanoyl-aminoacyl-2(S)-tetrazolylpyrrolidines were studied as prolyl oligopeptidase inhibitors. The com-
pounds were more potent than expected from the assumption that the tetrazole would also here be a bioisostere of the carboxylic acid
group and the corresponding carboxylic acids are at their best only weak inhibitors. The aminoacyl groups L-prolyl and L-alanyl gave
potent inhibitors with IC50 values of 12 and 129 nM, respectively. This was in line with typical prolyl oligopeptidase inhibitors,
however, we did observe a difference with N-methyl-L-alanyl, which gave potent inhibitors in typical prolyl oligopeptidase inhibitors
but not in our novel compound series. Furthermore, all studied 4-phenylbutanoyl-aminoacyl-2(S)-tetrazolylpyrrolidines decreased α-
synuclein dimerization at the concentration of 10 μM, also when they were only weak inhibitors of the proteolytic activity of the
enzyme with an IC50 value of 205 µM. Molecular docking studies revealed that the compounds are likely to bind differently to the
enzyme compared to typical prolyl oligopeptidase inhibitors represented in this study by 4-phenylbutanoyl-aminoacyl-2(S)-cyano-
pyrrolidines.
Prolyl oligopeptidase (PREP) is a serine protease with endo-
peptidase activity on short proline containing peptides cleaving
the peptide on the carboxyl side of the proline residue, and
many proline containing peptides, such as oxytocin and several
neuropeptides, have been identified as its substrates in vitro (see
for review Garcia-Horsman et al. 2007).1 PREP is mainly found
in the brain, more specifically in caudate nucleus and putamen,
hippocampus, and cortex.2 However, significant PREP activi-
ties and protein levels have been measured also in peripheral
tissues such as skeletal muscle,3 renal cortex, liver, ovaries, tes-
tis, and in ovarian and colorectal tumors.4-6 Alterations in the
enzyme activity of PREP have been observed in several dis-
eases, including Parkinson’s disease, Alzheimer’s disease,
Lewy body dementia,7 and in several types of tumors.8,9 Apart
from its proteolytic activity, PREP has also other biologically
important functions mediated by protein-protein interac-
tions.10,11 PREP is able to enhance dimerization of α-synuclein
(αSyn), the key player in cellular toxicity in Parkinson’s dis-
ease, via a direct protein-protein interaction.12 PREP has highly
flexible regions that are in equilibrium between many confor-
mations and inhibitor binding stabilizes these flexible regions
into one conformation.13 Inhibited PREP has been shown to in-
crease autophagy which is known to enhance clearance of ag-
gregated forms of proteins and decrease dimerization of αSyn
in vitro and in vivo.14,15
Almost all known highly potent PREP inhibitors are structur-
ally related to or recognizable mimetics of the peptide substrates
with distinct P1, P2 and P3 sites.16 The P1 moiety is mimicking
the important L-proline (Pro) residue in the substrate and it is
typically a pyrrolidine with or without an electrophilic group in
its 2-position. However, also five-membered heteroaryls such
as 2-thienyl and 2-furanyl in the P1-position have resulted in
potent inhibitors.17 The P2 moiety can be a wide variety of ami-
noacyl groups or aminoacyl mimetics with Pro being the most
preferred natural aminoacyl group, and the P3 moiety is typi-
cally a lipophilic acyl group. There are many examples of vari-
ations among the published inhibitors16, however, the two car-
bonyl groups of the connecting amide bonds have been difficult
to replace and only few inhibitors lack one or both of them in
their structures.18-21
The design for the new compounds came from one compound
synthesized by the last author of this paper in his earlier research
in the search for different replacements for the electrophilic
group in PREP inhibitors, where the tetrazolyl group gave a sur-
prisingly potent compound (unpublished data). In the present
study, our primary aim was to investigate if 4-phenylbutanoyl-
aminoacyl-2(S)-tetrazolylpyrrolidines as PREP inhibitors had
the same structure-activity relationship as typical PREP inhibi-
tor compound series such as 4-phenylbutanoyl-aminoacyl-pyr-
rolidines and 4-phenylbutanoyl-aminoacyl-2(S)-cyanopyrroli-
dines. A further aim was to study what effect the novel com-
pound series had on protein-protein-mediated functions of
PREP, such as catalysis of αSyn dimerization. We were in-
trigued by the fact that the tetrazole ring is quite different from
typical 2-substituents on the P1 pyrrolidine ring, especially its
polar character is exceptional.
.
Scheme 1. Synthesis of the compounds, where a specific aminoacyl group is always with the same lower case letter in compound
numbering. Reagents and conditions (a) 1. 10% aqueous Na2CO3, 4-phenylbutanoyl chloride / Et2O; (b) SOCl2 / MeOH, reflux; (c)
4-phenylbutanoyl chloride, DIPEA / DCM; (d) LiOH / water, MeOH; (e) 1. pivaloyl chloride (or in its place ethyl chloroformate for
4g), Et3N / DCM, 0 °C, 2. pyrrolidine, Et3N / DCM; (f) pyrrolidine / DCM; (g) 1. TFA / DCM, 0 °C, 2. 4-phenylbutanoyl chloride,
Et3N / DCM (or alternatively for 6f, 2. 1 M NaOH, 4-phenylbutanoyl chloride, / Et2O); (h) L-proline methyl ester, DIPEA / DCM;
(i) 1. ethyl chloroformate, Et3N / DCM, 0 °C, 2. L-proline methyl ester, Et3N / DCM; (j) 1. pivaloyl chloride, Et3N / DCM, 0 °C, 2.
L-prolinamide, Et3N, / DCM; (k) 1. ethyl chloroformate, Et3N / THF, -10 °C, 2. NH3 (7 M in MeOH); (l) 1. ethyl chloroformate, Et3N
/ DCM, 0 °C, 2. L-prolinamide, Et3N / DCM; (m) TFAA, Et3N / THF; (n) NaN3, NH4Cl / DMF, 100 °C.
There are PREP inhibitors with five-membered heteroaro-
matics, which look slightly similar to our tetrazoles.22,23 How-
ever, all of these have an electrophilic carbonyl group in exactly
the same position as the typical electrophile. In addition, the te-
trazole ring is negatively charged at physiological pH unlike the
five-membered heteroaromatics in the published PREP inhibi-
tors.
The synthetic routes for accessing the compounds in this
study are presented in Scheme 1. Compounds 7a (SUAM-
1221), 7b and 14a (KYP-2047) were obtained from our old
compound library at the University of Eastern Finland (14a was
also synthesized here only as a synthetic intermediate on the
route to 15a but not used in the testing). The connecting amide
bonds were synthesized using activation of carboxylic acid
groups to corresponding acid chlorides or mixed anhydrides.
These activation methods could not be used for non-N-alkylated
chiral amino acids due to their susceptibility for racemization,
and a milder activation to hydroxysuccinimide esters was used
for them. Furthermore, in the case of 2-aminoisobutyric acid
(Aib) the low solubility of the amino acid in the solvent of the
first step of the synthetic route had to be circumvented, and in
the case of N-methyl-L-alanine (MeAla) the slightly modified
synthetic route gave improved yields and more easily separable
intermediates. The 4-phenylbutanoyl-aminoacyl-L-pro-
linamides were converted to the corresponding nitriles by dehy-
dration with trifluoroacetic anhydride, and then further to the
corresponding tetrazoles with sodium azide.
The inhibition of the proteolytic activity of PREP (IC50) for
the compounds is presented in Table 1. The IC50 values were in
the beginning of the project determined using mouse brain ho-
mogenate, but we changed later to purified recombinant porcine
PREP. Most unsbstituted pyrrolidines and prolinamides were
tested with brain homogenate and all nitriles and tetrazoles were
tested with purified porcine PREP. The IC50 values for a few
compounds were determined with both homogenate and pure
enzyme to verify that the values were comparable.
In the beginning of the project earlier uncharted aminoacyl
groups, Aib, sarcosine (Sar), MeAla and β-alanine (βAla) were
evaluated at the P2 site in 4-phenylbutanoyl-aminoacyl-pyrrol-
idines, which is the most typical PREP inhibitor structure, and
compared to the two natural aminoacyl groups Pro and L-ala-
nine (Ala) which have been reported to give the most potent
compounds.24 In this study we did not carry out comparisons to
L-phenylalanine, L-methionine, L-leucine, L-valine and gly-
cine (Gly) as they have been previously shown to strongly de-
crease the inhibitory activity.24
Table 1. Inhibitory activities of the synthetized compounds.
Compound Xaa R IC50 (nM)enzyme IC50 95% CI
IC50 (nM)
homogenate IC50 95% CI
7a (SUAM-1221) Pro H 12 10-15 - -
7b Ala H 147 115-191 - -
7c MeAla H - - 298 142-571
7e Sar H - - 5141 3950-6604
7f D-Ala H - - 35180 12600-105300
7g Aib H - - 13510 8752-22570
7h bAla H - - 12080 7912-17790
13a Pro CONH2 4371 3841-4965 - -
13b Ala CONH2 - - 6213 3325-11340
13c MeAla CONH2 - - 28 800 9792-97350
13d Gly CONH2 - - 153 800 95 170-249 800
13e Sar CONH2 - - 457 000 329 600-637 700
14a (KYP-2047) Pro CN 0.86 -a 0.3 -a
14b Ala CN 4.06 2.0-7.7 3.28 2.06-5.22
14c MeAla CN 5.4 4.5-6.4 - -
14d Gly CN 220 117-454 264 138-493
14e Sar CN 269 -b - -
15a Pro tetrazolyl 12 9.9-14.7 - -
15b Ala tetrazolyl 129 71-225 91 55-146
15c MeAla tetrazolyl 27 180 22 150-33 410 - -
15d Gly tetrazolyl 205 400 -c - -
15e Sar tetrazolyl 10 640 8110-14 390 - -
10a Pro CO2H 3626 2821-4965 - -
10b Ala CO2H 17 540 14 100-22 100 - -
a Confidence interval could not be determined since IC50 value is lower than lowest used concentration.
b Confidence interval could not be determined since Hillslope is greater than -2.
c Confidence interval could not be determined since IC50 value is too high.
All explored aminoacyl groups were in fact one methyl/meth-
ylene group changes from Ala and of these only MeAla gave a
potent compound 7c. The other aminoacyl groups Sar, D-Ala,
Aib and βAla gave compounds 7e, 7f, 7g and 7h, respectively,
with significantly reduced inhibitory activities.
Pro, Ala, MeAla, Gly and Sar were selected as the aminoacyl
groups for our novel tetrazoles. They were synthesized via the
corresponding prolinamide and nitrile intermediates, which
were also tested for their inhibitory activities. As expected, the
prolinamide intermediates 13a-13e had only weak inhibitory
activities and the nitrile intermediates 14a-14e were highly po-
tent inhibitors. The electrophilic nitrile group is known to have
favorable interaction with the catalytic Ser554 residue at the ac-
tive site of the enzyme, and for 14a (which is the well-known
reference compound KYP-2047)25 this has been described as a
reversible covalent interaction.26,27 For the nitriles, also Pro, Ala
and MeAla gave the most potent inhibitors 14a, 14b and 14c,
with IC50 values of 0.86, 4.06 and 5.4 nM, respectively. These
IC50 values should be used with caution as at least 14a is a co-
valently binding compound with slow, tight binding enzyme ki-
netics.
Among our target tetrazoles 15a-15e, Pro and Ala gave the
most potent inhibitors 15a and 15b, with IC50 values of 12 and
129 nM, respectively. Surprisingly, MeAla gave only a weak
inhibitor 15c, which was over 200-fold lower in inhibitory ac-
tivity than 15b. It is obvious that the N-methyl group on Ala is
not favorable in combination with the tetrazole group. Gly and
Sar gave the tetrazoles 15d and 15e, which had weak inhibitory
activities of 205 and 10.6 µM, respectively. The carboxylic acid
analogues 10a and 10b of the most potent tetrazoles 15a and
15b, respectively, had only weak inhibitory activities in the mi-
cromolar range, indicating no bioisosterism between the te-
trazole and the carboxylic acid group in this series of com-
pounds.
For evaluating the ability of the tetrazoles 15a-15e to reduce
αSyn dimerization we used a slightly modified PCA (protein
fragment complementation assay) method described in Savo-
lainen et al. 2015.12 We used mouse N2A cells in the assay
which has high endogenous PREP activity (Suppl. Fig 1.). Re-
sults of the assay are shown in Figure 1. Interestingly, all te-
trazoles 15a-e decreased αSyn dimerization. The αSyn dimeri-
zation assay was performed at the concentration of 10 µM and
even tetrazole 15d with an IC50 value of 205 µM reduced αSyn
dimerization with the same magnitude as tetrazoles 15a and 15b
with IC50 values 12 and 129 nM, respectively.
Figure 1. Results of the αSyn-αSyn2 dimerization in PCA (protein fragment complementation assay) with 4 h treatment and 10 µM concen-
tration. Tetrazoles 15a-e reduced the amount of αSyn dimers 18-25% compared to control. 14a (KYP-2047), 14d and 14e were the only
compounds from nitrile group which were able to reduce αSyn dimerization. Carboxyl acids 10a and 10b were not able to reduce formation
of αSyn dimers. Lactacystin serves as positive control for αSyn dimerization. Data are presented as means+SEM (n≥3, *** p<0.001, **p<
0.01, *p<0.05)
We decided also to examine the nitrile intermediates as a
comparison. The nitrile 14a (KYP-2047) had been verified to
reduced αSyn dimerization in several earlier studies, but the
other nitriles had not been studied.12,14 To our surprise, the ni-
triles 14b and 14c with aminoacyl groups Ala and MeAla did
not have an effect on αSyn dimerization although they are 4-5
nM inhibitors of PREP, and on the other hand, the nitriles 14d
and 14e with aminoacyl groups Gly and Sar had an effect alt-
hough they are only 220-260 nM inhibitors of PREP. It is im-
portant to highlight here that only compounds 14a (89%,
p<0.05), 14d (81%, p<0.05), 15b (75%, p<0.01), 15c (75%,
p<0.05) and 15d (77%, p<0.05) had statistically significant de-
crease in aSyn dimerization (Student’s t-test compared to
DMSO control, n≥3).
The αSyn dimerization assay results for both nitriles and te-
trazoles clearly indicate that the structure-activity relationship
for affecting this function of PREP is slightly different from in-
hibiting the proteolytic activity. To study the binding of the ni-
triles 14a-e and tetrazoles 15a-e to PREP, molecular docking
studies were performed (Figure 2A-F). The binding pocket in-
cluded the commonly known S1, S2, and S3 subsites (Figure
2C). Among the nitriles, 14a is known to bind covalently to the
catalytically active serine residue (Ser554) at S1.28 Other ni-
triles could be assumed to orient similarly to 14a directing the
nitrile group towards S1 and Ser554 (Figure 2D). Indeed, all
nitriles could place the nitrile group at S1 and the phenyl group
at S3. The most potent nitriles 14a, 14b, and 14c directed the
nitrile group towards Ser554. However, in docking studies 14d
and 14e could not orient the nitrile group towards Ser554. This
could maybe explain why they are less potent inhibitors than
the other nitriles. In the docking protocol the covalent interac-
tion between the nitrile group and Ser554 was not assessed.
Thus, the possible covalent bond formation could actually force
the nitrile groups to S1.
Interestingly, none of the tetrazoles formed an interaction to
Ser554 even though they could place the tetrazole ring at S1.
The poses with the tetrazole ring at S1 were compared to the
poses of the corresponding nitriles with the nitrile group at S1
(Suppl. Fig. 2-6). The comparison revealed that the tetrazole
ring might be positioned in the binding pocket slightly differ-
ently than the nitrile group. This can be seen most clearly be-
tween compounds 14a and 15a, and compounds 14d and 15d.
The two most potent tetrazoles 15a and 15b were inclined to
form an interaction between their negatively charged tetrazole
group to the positively charged Arg643 instead of Ser554
(Suppl. Fig. 7 and 8). For the other tetrazoles the tetrazole ring
at S1 was not forming any interactions with amino acid residues
in the binding pocket (Suppl. Fig. 9-11). Moreover, the pose of
15e was tilted when compared to other tetrazoles or nitriles, and
its phenyl group positioned outside the pocket (Suppl. Fig. 11.).
The docking results proposed a putative binding pose in
which all the tetrazoles could fit to the binding pocket. In this
hypothetical pose the phenyl group was at S1 instead of S3
(Suppl. Fig. 12-16). Tetrazoles might prefer to position the lip-
ophilic benzene ring rather than the hydrophilic tetrazole ring
into the hydrophobic S1 pocket. The tetrazole ring does not
have a similar ability as the nitrile group to form a covalent
bond to Ser554, which is an important interaction for at least
some nitriles in anchoring them at S1. As a less hydrophilic
moiety, the nitrile group might also be more easily placed into
the S1 pocket than the tetrazole ring. Overall, these results sug-
gest that the tetrazoles might have two putative binding poses:
the phenyl group at S3 (Figure 2E) or at S1 (Figure 2F).
In conclusion, although the tetrazole group is a known com-
mon bioisostere for the carboxylic acid group, the tetrazole is
clearly not a bioisostere of a carboxylic acid group in PREP in-
hibitors. The tetrazoles were more potent inhibitors of the pro-
teolytic activity and αSyn dimerization catalyzing effect of
PREP than the corresponding carboxylic acids. The present
study further hypothesized that the tetrazoles might have an-
other binding mode in addition to the known binding mode of
PREP inhibitors. In this putative binding mode, the tetrazole
ring is placed at S3 and the phenyl group at S1. Remarkably, all
tetrazoles reduced αSyn dimerization despite the fact that some
of them only were weak inhibitors of the proteolytic activity.
These findings taken together possibly also indicate that there
could be another alternative binding site in enzyme, which af-
fects more the αSyn dimerization catalyzing effect than the pro-















































Figure 2. Putative binding site of the tetrazoles with PREP. (A) The crystal structure of PREP. The catalytically active serine residue (Ser554)
is marked with black, and the inhibitor-binding site is marked with green mesh. (B) The crystal structure of PREP from site of Figures C-F.
(C) The ligand-binding pocket with the S1, S2, and S3 subsites. Green indicates lipophilic, yellow aromatic, red electronegative, and blue
electropositive areas. (D) Compound 14a at the inhibitor-binding site. The nitrile points towards Ser554 and forms hydrogen bond to it (not
shown in the figure). (E) Compound 15a at the inhibitor-binding site in the commonly known binding mode. (F) A suggested hypothetical
binding mode for the tetrazoles with compound 15a as a representative compound.
EXPERIMENTAL SECTION
Synthesis and characterization of novel compounds. Synthe-
sis and characterization of all compounds are reported in detail
in supporting information.
Expression and purification of recombinant porcine PREP.
Porcine PREP enzyme was expressed and purified according
protocol described by Venäläinen et al. 2002.29
Determination of IC50 value. Preparation of mice brain ho-
mogenates and detailed procedure for in vitro assay for inhibi-
tory activity are found in supporting information.
PCA for αSyn dimerization. Detailed cell culture, procedure
and used DNA constructs are found in supporting information.
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